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ABSTRACT 
Introduction: Mycobacterium avium complex (MAC) is a leading cause of 
pulmonary disease (PD), even in those with intact immunity, representing 
about 30% of the cases of pleuropulmonary mycobacterial infection. Based 
on previous studies, macrolides are the only agents used in the treatment of 
MAC disease for which there is a correlation between in vitro susceptibility 
and in vivo (clinical) response. However, resistance develops rapidly if single- 
agent treatment is used. Data regarding treatment of macrolide-resistant MAC 
(MRMAC) and multidrug-resistant MAC (MDRMAC) are sparse. 
Case summary: A 50-year-old, HIV-negative white man, weighing 53.6 kg, with 
severe chronic obstructive pulmonary disease and bronchiectasis was initially 
on treatment for MAC-PD and MRMAC. The patient was followed between 
1999 and 2006. His treatment history revealed that in addition to the multiple 
drugs administered during the course of his illness, thalidomide, interferon-y, 
and mefloquine were also administered. The patient died -7 years later due to 
respiratory failure and overwhelming infection. 
Conclusions: This case report describes the use of mefloquine as adjunct 
treatment in an HIV-negative patient with MDRMAC-PD and discusses the asso- 
ciated outcomes of drug resistance. (Curr Ther Res Clin Exp. 2007;68:421-429) 
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INTRODUCTION 
Mycobacterium avium complex (MAC) is recognized as one of the most common 
nontuberculous mycobacterial  pathogens found in humans and accounts for 
~30% of all mycobacterial  infections. 1 It has been known to cause disseminated 
disease in those who suffer from HIV infection, where it typical ly presents 
as disseminated isease. 1 It has also been found to be a cause of pulmonary 
disease (PD) in non-HIV patients and those with apparently intact immunity. 1 
Although M avium-intracellulare (MAI) complex can be isolated from the spu- 
tum of apparently healthy individuals, it might cause lung disease and progres- 
sion of underlying lung disease leading to respiratory failure and even death. 2
HIV-negative patients with underlying lung disease may acquire MAC infection. 2
However, it has been suggested that MAC might cause progressive lung disease 
in patients without underlying lung disease, particularly in middle-aged and 
elderly women. It has also been suggested that deficient interferon-~/ (INF-~/) 
pathways or an abnormal C~l-antiprotease g ne might play a predisposing role 
in some patients. 3 Patients with chest wall deformities uch as kyphoscoliosis 
and pectus excavatum are also at greater isk for acquiring MAC infection. 4 
The clinical presentat ion of MAC-PD infection in an HIV-negative host varies 
and depends on the population studied. Table I i l lustrates the clinical classifi- 
cation based on its presentat ion i an HIV-negative patient. 5 In this classifica- 
tion, complex MAC includes cases in which earlier t reatment has failed or the 
disease process is recurr ing and progressing. Because of the prevalence of 
M avium and MAI in the environment, it is not surprising that some patients 
might be infected by more than a single strain. 6 However, a single strain of 
Mavium tends to persist in patients with advanced fibrocavitary disease. 6 Patients 
with f ibronodular bronchiectasis might develop different strains over time, sug- 
Table I. Clinical classification based on available evidence, expert opinion, and clini- 
cal observation in the case report on the use of mefloquine in multidrug- 
resistant Mycobacterium avium complex pulmonary disease in an HIV-negative 
patient. 
Clinical Categories Suggested Treatment Options 
Hot tub lung 
"Simple colonization" 
Simple persisters and/or 
disease 
Complex disease 
Complicated disease 
Avoidance, steroids, or 2 drugs such as ethambutol 
and macrolide 
Bronchial toilet/nebulized treatment with 
aminoglycoside 
Clarithromycin or azithromycin with ethambutol 
Clarithromycin, ethambutol, and rifabutin or 
azithromycin, ethambutol, and rifabutin 
Customized regimen based on drug sensitivity and/or 
surgery 
Adapted with permission. 5
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gesting asusceptibility othe organism that allows reinfection after it has been 
eradicated. 6 Reasons for treatment failure in these chronic cases include drug 
resistance, poor drug penetration i to the damaged lung, patient intolerance 
to treatment, or erratic compliance. The relative resistance to penetration of 
antimycobacterials into lung tissue is presumably due to the lipophilicity of the 
cell wall. 7 Moreover, 50% of all cases of treatment failure might be attributed to 
MAC isolates that are resistant to macrolides. 8,9 Studies 1°,11 of clarithromycin- 
resistant MAC strains isolated from mice and patients with confirmed iagnoses 
of MAIs by exposing mycobacteria to mefloquine, in vitro susceptibility esting, 
and human macrophage data, have demonstrated activity of mefloquine on 
MAC. Mefloquine, moxifloxacin, and ethambutol, combined, were evaluated 
against both clarithromycin-resistant (CLR-R) and CLR-susceptible (CLR-S) 
MAC. Mefloquine (40 mg/kg/day), moxifloxacin (100 mg/kg/day), or ethambutol 
(100 mg/kg/day) was administered to mice for 4 weeks. Mefloquine was bacte- 
ricidal, whereas moxifloxacin and ethambutol were bacteriostatic against both 
MAC strain 101 CLR-R and CLR-S. The combination of mefloquine and etham- 
butol reduced (P < 0.05, for comparison with controls), and the combination of 
mefloquine and moxifloxacin significantly reduced, the load of CLR-R in both 
the liver and the spleen. Treatment with all 3 drugs was associated with ~1 log 
reduction of CLR-R after 1 week, 2.1 log reductions of CLR-R after 4 weeks, and 
2.17 log reductions in MAC/mL blood. Treatment of MAC 101 CLR-S strain had 
comparable results. 1°,11 
In this case report, we describe the first HIV-negative patient with multidrug- 
resistant MAC (MDRMAC) and MAC-PD, failing standard treatment, o whose 
regimen mefloquine was added. A search of the literature using the PubMed 
database and searching from 1999 to 2007 with key words mefloquine, MAC, 
and HIV, did not identify any other case report on the use of mefloquine in an 
HIV-negative host with resistant MAC-PD. 
CASE REPORT 
A 50-year-old, HIV-negative, white man, weighing 53.6 kg, was admitted to the 
Louisiana State University Hospital Sciences Center affiliate Hospital at the 
Kenner Regional Campus with increasing dyspnea, cough, intermittent fever, 
and progressive fatigue. His medical history revealed tuberculosis, chronic 
obstructive pulmonary disease (COPD), bronchiectasis, and MAC-PD. Current 
diagnosis was based on underlying lung disease, persistent sputum cultures 
exhibiting MAC infection, and the absence of other bacterial growth on 
respiratory specimens. The patient's medical report also revealed a 30 pack- 
year smoking history and no known occupational exposure or substance 
abuse. A review of the patient's previous laboratory findings revealed a normal 
immunoglobulin panel and a normal CD4/CD8 ratio. His HIV test was negative, 
and during the course of his illness, his CD4 and CD8 INF- 7 levels in peripheral 
whole blood-by-flow cytometry were normal. He had initially received empiric 
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treatment for MAC-PD and later for macrolide-resistant MAC (MRMAC) based 
on serial culture data from 1999 to 2006 (Table tt). During the course of his 
follow-up, culture and sensitivity testing were performed at various intervals 
by the Medical Center of Louisiana New Orleans Hospital Laboratory, New 
Orleans, Louisiana; the University of Texas Health Center, Tyler, Texas; and 
the National Jewish Medical and Research Center, Denver, Colorado. The 
patient received intermittent broad-spectrum antibiotics and nebulization for 
the treatment of acute exacerbation of bronchiectasis. The patient eventually 
developed MDRMAC confirmed by serial culture results. Because of extensive 
bilateral disease and poor respiratory reserve, surgery was not an option. 
The patient had also previously been enrolled in a randomized, double-blind, 
placebo-controlled trial in which he received inhaled INF- 7 as part of a thrice 
weekly standard triple-drug treatment with a macrolide, ethambutol, and 
rifampin with and without inhaled INF- 7. An interim analysis of the trial data did 
not reveal any difference in outcomes between the 2 groups, and the trial was 
terminated after 52 weeks. 12 The patient was later treated with thalidomide for 
-1 month but discontinued ue to extreme drowsiness (Table tt). Because of 
the patient's multidrug-resistant profile, he was also treated with mefloquine 
1000 mg/d for 3 months. No adverse events (AEs) related to treatment were 
noted. However, potential AEs were monitored by telephone inquiries and eval- 
uation at the follow-up visits to the Medical Center of Louisiana New Orleans 
Hospital clinic. At his 3-month follow-up visit, the results of his sputum culture 
again revealed MDRMAC, suggesting colonization. 
On admission, physical examination revealed a cachectic man exhibiting 
accessory respiratory muscle use with an oxygen saturation of 82% on room 
air. The patient had temporal wasting, pale conjunctiva, and mucosa; his tra- 
chea was deviated to the right, and there was mild jugular venous distension. 
Lung examination revealed significant egophony and whispered pectoriloquy 
on the right side with decreased breath sounds in the base. Coarse crackles 
were heard in the left lung. Other aspects of his physical examination were 
noncontributory. A computed tomography scan of the chest revealed severe 
bilateral disease with right lung destruction and multiple pulmonary nodules 
and cavities. The patient was treated with intravenous piperacillin-tazobactam 
3.375 g every 6 hours and intravenous ciprofloxacin 400 mg every 8 hours for 
7 days along with daily nebulized tobramycin and albuterol 2.5 mg/3 cc every 
4 hours for exacerbation of bronchiectasis. His cultures for MAC remained 
positive throughout the admission. At discharge, he was again placed on oral 
mefloquine 1 g QD along with ethambutol oral 800 mg QD. Throughout his 
clinical course, he was reported as being compliant (ie, having administered 
>80% of drug) with mefloquine treatment with no reports of AEs. The patient 
was closely monitored and questioned by telephone regarding potential gas- 
trointestinal nd neuropsychiatric AEs. However, no AEs were reported. After 
~1 month, the patient was readmitted for respiratory failure and died 10 days 
after hospital admission. An autopsy was not performed. 
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DISCUSSION 
Clinical trials 13,14 have not found susceptibility testing to medications used 
for MAC to be uniformly useful. The American Thoracic Society (ATS) and 
the Infectious Diseases Society of America's (IDSA) 13 2007 statement on non- 
tuberculous mycobacterial diseases recommends against testing of agents 
other than clarithromycin. With the exception of clarithromycin, the role and 
the predictability of in vitro susceptibility testing of MAC are controversial. 
However, the National Committee for Clinical Laboratory Standards (NCCLS) 14 
2000 guidelines for susceptibility esting of mycobacteria, Nocardia, and other 
aerobic actinomycetes, recommend that clarithromycin susceptibility testing 
be done for respiratory MAC isolates in patients with PD. The NCCLS guidelines 
also recommend that clarithromycin susceptibility esting be done on respira- 
tory isolates in patients who received prior macrolide treatment and on those 
who relapse while receiving macrolide treatment. In a randomized, double- 
blind, dose-ranging study 15 in patients with AIDS, clarithromycin was found to 
be the only medication to have an association between clinical response and 
the results of in vitro susceptibility esting. In this report, adjusting treatment 
to sensitivity testing results improved sputum culture conversion in MAC lung 
disease, but studies 16 do not reveal similar benefits having been found with 
drugs such as ethambutol and rifampin. Relative resistance to individual medi- 
cations notwithstanding, a possible synergistic effect of combined treatment 
on MAC, might explain the lack of an association between sensitivity testing 
and clinical outcomes. 17The sputum conversion rates, however, have been 
found to be significantly lower in patients who are infected with CLR-R strains, 
have had prior treatment, or were acid-fast bacillus smear positive at entry 
irrespective of type and extent of disease. 18 
According to the ATS/IDSA 2007 recommended guidelines, 13patients with 
nodular/bronchiectatic d sease should receive a thrice weekly regimen of 
clarithromycin (1000 mg) or azithromycin (500 mg), rifampin (600 mg), and 
ethambutol (25 mg/kg). Patients with fibrocavitary MAC lung disease or severe 
nodular/bronchiectatic disease should receive a daily regimen of clarithromy- 
cin (500-1000 mg) or azithromycin (250 mg), rifampin (600 mg) or rifabutin 
(150-300 mg), and ethambutol (15 mg/kg) along with the consideration of the 
administration of a 3 × weekly amikacin or streptomycin (10-15 mg/kg) early 
treatment. Typically, treatment should be continued until the patient is culture 
negative for -1 year. 
Data regarding treatment of MRMAC and MDRMAC are sparse. Risk fac- 
tors that might contribute to the development of macrolide resistance include 
extended macrolide monotherapy or macrolide with fluoroquinolone adjunct 
treatment. 19 Mefloquine (a derivative of 4-quinolinemethanol), used for 
the prophylaxis of chloroquine-resistant Plasmodium falciparum malaria, 
might be useful adjunct treatment for MDRMAC, although human studies 
are lacking. The mechanism of action is not clear, and it has been sug- 
gested that, based on its effect on P falciparum, mefloquine might have 
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some effect on the membranes of MAC organisms. 11 Experimental  and in vitro 
studies 18-2° found that mefloquine is bactericidal against both CLR-R and CLR-S 
strains.  
The advantage of mefloquine is its long t~ (6.5-33 days) and synergy with 
ethambutol.  1°,11 It is active against MAC strains in vitro and can achieve 60 to 
80 x greater intracellular concentrat ions than extracellular concentrations. The 
Bermudez et a111 experimental  study tested MAC strains resistant o clarithro- 
mycin, isoniazid, streptomycin, pyrazinamide, and rifampin, and found these to 
be susceptible to mefloquine. Ethambutol and mefloquine together were also 
active in the blood to a greater extent han ethambutol  alone. 11 Limited human 
postmortem data indicate that mefloquine (in a prophylactic dosing regimen) 
achieves a high level of 190 mg/kg in the lung. 2° 
In our case, we added mef loquine 2 t imes to our patient's regimen 
(20 mg/kg QD) due to severe and progress ive disease and the failing of all 
other  t reatment .  A l i terature search  from 1999 to 2007 using the PubMed 
database and key words mefloquine, MAC, and HIV, did not identi fy any other  
case repor t  on the use of mef loquine in a pat ient with res istant MAC-PD in 
an HIV-negative host. However, Nannini et a121 repor ted  its successful  use 
along with linezolid, moxif loxacin, and granulocyte  colony-st imulat ing fac- 
tor in d isseminated MAC infection in an HIV-negative pat ient with chronic  
lymphocyt ic  leukemia. In our case, no AEs were observed or repor ted  
during the course of t reatment .  No obvious benefit  was noted, however, 
perhaps  due to the relat ively short  t reatment  per iod or other  factors of 
comorb id i ty  (ie, COPD and bronchiectas is)  in this patient. Further  human 
studies are needed to establ ish potential  eff icacy and long-term tolerabi l i ty 
with mef loquine t reatment  for severe MDRMAC. 
CONCLUSION 
This report  descr ibes the use of mefloquine as adjunct t reatment in an HIV- 
negative patient with MDRMAC-PD. Mefloquine appeared to be well tolerated 
by the patient. 
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